Vitamin D2 can lower vitamin D3 levels in the bloodstream
A popular vitamin D supplement form may carry an unexpected biochemical trade-off. A 2025 meta-analysis published in Nutrition Reviews found that vitamin D2 supplementation was associated with lower circulating 25-hydroxyvitamin D3, the form the body naturally produces after sunlight exposure and the one many researchers consider more efficient at sustaining vitamin D status.
The finding matters because vitamin D2 and vitamin D3 are often treated as interchangeable on pharmacy shelves and in clinical conversations. They are not metabolically identical. Vitamin D2, also called ergocalciferol, is commonly derived from fungi or yeast exposed to ultraviolet light. Vitamin D3, or cholecalciferol, is the same form produced in human skin after ultraviolet B exposure and is also available in animal-free versions such as lichen-derived preparations.
The review pooled 20 studies, with 11 contributing to the main meta-analysis. Across those trials, people receiving vitamin D2 had significantly lower levels of 25-hydroxyvitamin D3 than controls. The average reduction came in at roughly 9 to 18 nanomoles per liter, depending on the analytic approach. The signal was consistent enough to raise a practical question for clinicians and dietitians: when the goal is to optimize vitamin D status, does the supplement label matter more than is often assumed?
It does.
The biology suggests a competition between two related metabolites
Vitamin D does not act as a single static compound. Once ingested or synthesized in skin, it undergoes processing in the liver, where it is converted into 25-hydroxyvitamin D, the main circulating form used in blood tests. Vitamin D2 generates 25-hydroxyvitamin D2, while vitamin D3 generates 25-hydroxyvitamin D3. The meta-analysis found that when D2 rises, D3 can fall, implying a regulatory interaction rather than a simple additive effect.
A leading explanation is homeostatic control. When concentrations of vitamin D metabolites increase, the body may speed breakdown and clearance to preserve balance. In that framework, taking D2 may trigger pathways that dispose of existing D3-derived metabolites more quickly. Earlier experiments have suggested a reciprocal pattern as well, with D3 supplementation sometimes reducing D2-derived compounds. The physiology is still incomplete, but the direction of travel is clear enough to shape supplement selection discussions.
For most patients, the issue is not whether D2 can work at all. It can. The more relevant question is whether D3 raises and maintains vitamin D stores more reliably over time. Current guidance from the U.S. National Institutes of Health reflects that distinction, indicating that D3 tends to increase blood vitamin D levels more effectively and keep them elevated longer than D2.
Bone, muscle, and immune function make the difference clinically relevant
Vitamin D has long been tied to calcium absorption and bone health, but its effects extend beyond the skeleton. It plays roles in muscle function, nerve signaling, and immune regulation. In the UK, people are advised to consider 10 micrograms of vitamin D daily during the darker months, when skin synthesis drops sharply because sunlight is too weak for adequate production.
That seasonal context gives the new data additional weight. If many patients are taking supplements to compensate for reduced sun exposure, then the relative performance of D2 and D3 becomes a real-world issue rather than a biochemical curiosity. A supplement that raises total vitamin D while lowering the body’s own D3-derived circulating pool may still be useful, but it may not be the best fit for routine use when other options are available.
Plant-based and animal-free D3 sources now exist, including lichen-derived formulations. That matters for people avoiding animal products, because D3 has historically been associated with lanolin from sheep’s wool. Access to non-animal D3 narrows one of the main practical reasons for choosing D2 in the first place.
Immune signaling points toward a wider difference between D2 and D3
The vitamin D story is no longer confined to bone metabolism. Earlier work from the University of Surrey examined blood gene activity after supplementation and found notable differences between D2 and D3. In that study, vitamin D3 appeared to stimulate type I interferon signaling, while vitamin D2 did not. Type I interferons are key signaling proteins in the early immune response to viruses and other pathogens.
Those findings do not prove that vitamin D3 prevents infections in day-to-day practice. Gene-expression shifts are not the same thing as fewer fevers, fewer positive viral tests, or fewer hospital visits. Still, the biology is plausible. A nutrient that better supports interferon-related pathways could help prime early innate defense, especially when baseline vitamin D stores are low.
The clinical takeaway is careful rather than sweeping. D3 may have a broader functional profile than D2, but immune effects still need to be tied to hard outcomes before supplement advice is rewritten around infection prevention claims.
Newer analyses complicate the picture without erasing the signal
A separate 2026 systematic review and meta-analysis examined 26 randomized trials of vitamin D2 and found that D2 supplementation reduced parathyroid hormone and produced a small rise in blood calcium. Those results matter because they show D2 continues to exert meaningful biological effects, even if it is associated with lower circulating D3. The supplement is active; it is simply not metabolically interchangeable with D3.
That nuance helps prevent overcorrection. The finding that D2 lowers D3 does not mean D2 is ineffective or unsafe by default. It means the body responds differently to the two forms, and those differences may influence which preparation should be preferred when clinicians are choosing a supplement for routine deficiency prevention or maintenance.
Comparative meta-analyses have pointed in the same direction. One analysis of 24 studies found D3 more effective than D2 at improving overall vitamin D status, and another focused on frequent dosing arrived at a similar conclusion. The newer evidence does not overturn those comparisons; it reinforces them while adding a specific biochemical detail about the D3 decline.
The remaining question is whether the blood difference changes health outcomes
The central unresolved issue is not whether D2 can lower 25-hydroxyvitamin D3. The randomized trial evidence strongly suggests that it can. The harder question is whether that reduction changes fractures, infection rates, muscle function, or other patient-centered outcomes over time.
That question will take more than laboratory assays to answer. Future studies need to separate the metabolism of D2 and D3 more clearly, track immune effects against clinical endpoints, and determine whether D3 should become the default choice for routine supplementation when no individual reason exists to use D2. For now, the evidence supports a cautious but practical conclusion: vitamin D supplements are not interchangeable simply because they share the same label category.
Professor Martin Warren of the Quadram Institute framed the public health stakes in direct terms, noting that winter vitamin D deficiency remains a significant concern in the UK. The immediate challenge is choosing the form that gives the most reliable biochemical response, especially in populations likely to need supplementation for months at a time. The remaining gap is clinical outcome data, and until those studies are in hand, the smarter supplement is the one with the stronger and more durable effect on vitamin D status.